{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:08:47Z","timestamp":1792670927032,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005876","name":"Research Council for Biosciences and Environment","doi-asserted-by":"publisher","award":["332454"],"award-info":[{"award-number":["332454"]}],"id":[{"id":"10.13039\/501100005876","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Research Council of Finland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004012","name":"Jane and Aatos Erkko Fundation","doi-asserted-by":"publisher","award":["220031"],"award-info":[{"award-number":["220031"]}],"id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.biopha.2025.118647","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T22:52:20Z","timestamp":1760395940000},"page":"118647","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Targeting acute myeloid leukemia resistance with two novel combinations demonstrate superior efficacy in TP53, HLA-B, MUC4 and FLT3 mutations"],"prefix":"10.1016","volume":"192","author":[{"given":"Elham","family":"Gholizadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Zangene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alun","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Kontro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4324-8706","authenticated-orcid":false,"given":"Caroline A.","family":"Heckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohieddin","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118647_bib1","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.118647_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104424","article-title":"Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy","volume":"201","author":"Ruglioni","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.biopha.2025.118647_bib3","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118647_bib4","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2016-01-693879","article-title":"Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia","volume":"128","author":"Metzeler","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.118647_bib5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s12185-016-1942-1","article-title":"TP53 mutations in older adults with acute myeloid leukemia","volume":"103","author":"Yanada","year":"2016","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.biopha.2025.118647_bib6","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1200\/JCO.1995.13.4.1009","article-title":"Implications of the p53 tumor-suppressor gene in clinical oncology","volume":"13","author":"Chang","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118647_bib7","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0092-8674(00)81871-1","article-title":"p53, the cellular gatekeeper for growth and division","volume":"88","author":"Levine","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2025.118647_bib8","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nrc864","article-title":"Live or let die: the cell\u2019s response to p53","volume":"2","author":"Vousden","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2025.118647_bib9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the p53 network","volume":"408","author":"Vogelstein","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118647_bib10","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/BF01220804","article-title":"The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers","volume":"122","author":"Hamada","year":"1996","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118647_bib11","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118647_bib12","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1038\/s41375-018-0351-2","article-title":"TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups","volume":"33","author":"Haase","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2025.118647_bib13","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/EDBK_199519","article-title":"Acute myeloid leukemia: the good, the bad, and the ugly","volume":"38","author":"Kuykendall","year":"2018","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.biopha.2025.118647_bib14","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2005-08-3453","article-title":"Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia","volume":"107","author":"Stirewalt","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.118647_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14051164","article-title":"A. Role of biomarkers in FLT3 AML","volume":"14","author":"Nitika","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2025.118647_bib16","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10555-021-09959-1","article-title":"Mucins reprogram stemness, metabolism and promote chemoresistance during cancer progression","volume":"40","author":"Marimuthu","year":"2021","journal-title":"Cancer Metastas.. Rev."},{"key":"10.1016\/j.biopha.2025.118647_bib17","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1080\/09674845.2020.1754583","article-title":"Prognostic value of bone marrow MUC4 expression in acute myeloid leukaemia","volume":"77","author":"Abdelhady","year":"2020","journal-title":"Br. J. Biomed. Sci."},{"key":"10.1016\/j.biopha.2025.118647_bib18","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s43018-020-00140-1","article-title":"Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44","volume":"1","author":"Cummings","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.biopha.2025.118647_bib19","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1126\/science.aao4572","article-title":"Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy","volume":"359","author":"Chowell","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.biopha.2025.118647_bib20","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/bjh.19519","article-title":"Combination therapy with novel agents for acute myeloid leukaemia: insights into treatment of a heterogenous disease","volume":"205","author":"Jen","year":"2024","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.biopha.2025.118647_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.562558","article-title":"Venetoclax-based combinations in acute myeloid leukemia: current evidence and future directions","volume":"10","author":"Samra","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2025.118647_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/genes10110935","article-title":"Zebrafish models of Cancer-New insights on modeling human cancer in a Non-Mammalian vertebrate","volume":"10","author":"Hason","year":"2019","journal-title":"Genes"},{"key":"10.1016\/j.biopha.2025.118647_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/biology10040252","article-title":"The zebrafish xenograft models for investigating cancer and cancer therapeutics","volume":"10","author":"Gamble","year":"2021","journal-title":"Biology"},{"key":"10.1016\/j.biopha.2025.118647_bib24","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3324\/haematol.2010.031401","article-title":"Leukemic cell xenograft in zebrafish embryo for investigating drug efficacy","volume":"96","author":"Pruvot","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2025.118647_bib25","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.leukres.2012.06.001","article-title":"The zebrafish as a tool in leukemia research","volume":"36","author":"Teittinen","year":"2012","journal-title":"Leuk. Res."},{"key":"10.1016\/j.biopha.2025.118647_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41389-024-00510-9","article-title":"Designing patient-oriented combination therapies for acute myeloid leukemia based on efficacy\/toxicity integration and bipartite network modeling","volume":"13","author":"Mirzaie","year":"2024","journal-title":"Oncogenesis"},{"key":"10.1016\/j.biopha.2025.118647_bib27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beha.2019.05.008","article-title":"Venetoclax-based therapies for acute myeloid leukemia","volume":"32","author":"Guerra","year":"2019","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.biopha.2025.118647_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720986646","article-title":"Venetoclax-containing regimens in acute myeloid leukemia","volume":"12","author":"Aldoss","year":"2021","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.biopha.2025.118647_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.101036","article-title":"Acute myeloid leukemia resistant to venetoclax-based therapy: what does the future hold?","volume":"59","author":"Dhakal","year":"2023","journal-title":"Blood Rev."},{"key":"10.1016\/j.biopha.2025.118647_bib30","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1182\/blood.V124.21.2379.2379","article-title":"Leukemia associated TP53 mutations in AML patients ARE strongly associated with complex karyotype and poor outcome","volume":"124","author":"Ferrari","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.118647_bib31","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/asheducation-2016.1.348","article-title":"Mutations in AML: prognostic and therapeutic implications","volume":"2016","author":"DiNardo","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.biopha.2025.118647_bib32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0378-4274(01)00340-X","article-title":"Micronucleus formation in mouse bone marrow cells in vivo in response to trans, trans-muconaldehyde","volume":"121","author":"Oshiro","year":"2001","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.biopha.2025.118647_bib33","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2025.118647_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143456","article-title":"Targeting acute myeloid leukemia with venetoclax; biomarkers for sensitivity and rationale for Venetoclax-Based combination therapies","volume":"14","author":"Griffioen","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2025.118647_bib35","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccell.2022.02.006","article-title":"The proteogenomic subtypes of acute myeloid leukemia","volume":"40","author":"Jayavelu","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2025.118647_bib36","doi-asserted-by":"crossref","first-page":"8488","DOI":"10.1093\/nar\/gkab627","article-title":"Systematic identification of novel cancer genes through analysis of deep shRNA perturbation screens","volume":"49","author":"Montazeri","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2025.118647_bib37","article-title":"Protocol to evaluate hyperlipidemia in zebrafish larvae","volume":"3","author":"Balamurugan","year":"2022","journal-title":"STAR Protoc."},{"key":"10.1016\/j.biopha.2025.118647_bib38","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11033-023-08912-5","article-title":"Selection of reference genes in liproxstatin-1-treated K562 leukemia cells via RT-qPCR and RNA sequencing","volume":"51","author":"Dong","year":"2024","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.biopha.2025.118647_bib39","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s41598-024-84802-5","article-title":"Identification of new reference genes with stable expression patterns for cell cycle experiments in human leukemia cell lines","volume":"15","author":"T\u00f3th","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118647_bib40","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12859-019-2809-2","article-title":"Conventionally used reference genes are not outstanding for normalization of gene expression in human cancer research","volume":"20","author":"Jo","year":"2019","journal-title":"BMC Bioinforma."},{"key":"10.1016\/j.biopha.2025.118647_bib41","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1745-7270.2007.00283.x","article-title":"Validation of zebrafish (Danio rerio) reference genes for quantitative real-time RT-PCR normalization","volume":"39","author":"Tang","year":"2007","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.biopha.2025.118647_bib42","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s41419-024-07140-4","article-title":"Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine","volume":"15","author":"Tambe","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2025.118647_bib43","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood.2024024968","article-title":"Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial","volume":"145","author":"Kyt\u00f6l\u00e4","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.118647_bib44","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome","volume":"119","author":"R\u00fccker","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.118647_bib45","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.59","article-title":"TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution","volume":"5","author":"Hou","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.biopha.2025.118647_bib46","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/nrc2763","article-title":"Awakening guardian angels: drugging the p53 pathway","volume":"9","author":"Brown","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2025.118647_bib47","article-title":"Exploring mechanisms of action in combinatorial therapies through solubility alterations: advancing AML treatment","author":"Gholizadeh","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.biopha.2025.118647_bib48","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2025.118647_bib49","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/2159-8290.CD-17-1119","article-title":"First-in-class ERK1\/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study","volume":"8","author":"Sullivan","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2025.118647_bib50","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1631\/jzus.B2000842","article-title":"Blocking the JAK2\/STAT3 and ERK pathways suppresses the proliferation of gastrointestinal cancers by inducing apoptosis","volume":"22","author":"Wang","year":"2021","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"10.1016\/j.biopha.2025.118647_bib51","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00109-012-0886-z","article-title":"Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for \u2018vertical\u2019 and \u2018lateral\u2019 combination strategies","volume":"90","author":"Ricciardi","year":"2012","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.biopha.2025.118647_bib52","doi-asserted-by":"crossref","first-page":"10853","DOI":"10.1073\/pnas.0804821105","article-title":"mTORC1 promotes survival through translational control of Mcl-1","volume":"105","author":"Mills","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2025.118647_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032232","article-title":"The mucin MUC4 and its membrane partner ErbB2 regulate biological properties of human CAPAN-2 pancreatic cancer cells via different signalling pathways","volume":"7","author":"Jonckheere","year":"2012","journal-title":"PLOS One"},{"key":"10.1016\/j.biopha.2025.118647_bib54","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.coi.2020.05.008","article-title":"Polymorphisms of HLA-B: influences on assembly and immunity","volume":"64","author":"Olson","year":"2020","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.biopha.2025.118647_bib55","article-title":"Shifting beyond classical drug synergy in combinatorial therapy through solubility alterations","author":"Jafari","year":"2025","journal-title":"Res. Sq."},{"key":"10.1016\/j.biopha.2025.118647_bib56","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis","volume":"99","author":"Thiede","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.118647_bib57","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.V100.1.59","article-title":"Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease","volume":"100","author":"Schnittger","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.118647_bib58","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/ajh.21458","article-title":"FLT3 mutations have no prognostic impact in elderly patients with acute myeloid leukemia and normal karyotype","volume":"84","author":"Ferrara","year":"2009","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.biopha.2025.118647_bib59","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41408-023-00911-w","article-title":"Treatment of older adults with FLT3-mutated AML: emerging paradigms and the role of frontline FLT3 inhibitors","volume":"13","author":"Short","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.biopha.2025.118647_bib60","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1038\/s41467-022-29793-5","article-title":"Bipartite network models to design combination therapies in acute myeloid leukaemia","volume":"13","author":"Jafari","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118647_bib61","article-title":"NIMAA: an R\/CRAN package to accomplish NomInal data mining AnAlysis","author":"Jafari","year":"2022","journal-title":"bioRxiv"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225008418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225008418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:43:12Z","timestamp":1775781792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225008418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":61,"alternative-id":["S0753332225008418"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118647","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting acute myeloid leukemia resistance with two novel combinations demonstrate superior efficacy in TP53, HLA-B, MUC4 and FLT3 mutations","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118647","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118647"}}